HiCM-188 — iPSC-Derived Cardiomyocytes for Advanced Heart Failure, Phase 3
—
| Trial ID | NCT07496372 ↗ |
|---|---|
| Sponsor | HELP Therapeutics Co., Ltd. · China |
| Cell Source | 유도만능줄기세포 (iPSC) · allogeneic |
| Indication | 심부전 · Heart Failure |
| Phase | PHASE 3 |
| Status | RECRUITING |
| Delivery Route | intramyocardial injection (combined with CABG) |
| Enrollment | 80 |
| Publication | — |
Trial Design
HiCM-188 is a cardiomyocyte therapy derived from human induced pluripotent stem cells (iPSCs). This study is a Phase 3 pivotal clinical trial evaluating the administration of HiCM-188 alongside coronary artery bypass grafting (CABG) in patients with advanced heart failure. The primary endpoint is the change in six-minute walk distance at 12 months — an outcome that reflects actual improvement in exercise capacity rather than structural or imaging metrics alone.
Clinical Significance
The entry of an iPSC-based cell therapy into Phase 3 — with the explicit aim of generating the evidence needed for regulatory approval — represents a meaningful step forward. Heart failure involves both structural cardiac damage and functional deterioration, making it essential that any cell therapy demonstrates benefit in terms of real-world functional recovery.
Reasons HiCM-188 is drawing attention:
- iPSC-derived functional cells — cardiomyocytes differentiated directly for therapeutic use
- Advanced heart failure population — a high-risk group with limited options under standard-of-care
- Functional outcome focus — six-minute walk distance as the primary endpoint
- Combined surgical strategy — cell therapy integrated with CABG
Limitations and Discussion
Long-term safety of iPSC-derived cells, the risk of arrhythmia, and the degree of engraftment remain critical questions to resolve. Because HiCM-188 is administered alongside CABG, interpreting whether functional improvement is attributable to the surgical procedure or the cell therapy will be methodologically important. Although this is a Phase 3 study with 80 participants, long-term follow-up data will be necessary to establish the full clinical meaning of any observed benefit.